The involvement of NRF2 in lung cancer

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2013, Pages

  Bauer, Alison K ^a   Hill, Thomas ^a   Alexander, Carla Maria ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR STRESS RESPONSE; KEY REGULATORS; LUNG CANCER; MOUSE MODELS; NUCLEAR FACTORS; THERAPEUTIC STRATEGY;

DISEASES; MAMMALS;

BIOLOGICAL ORGANS;

CARBONYL REDUCTASE; CELL DNA; CISPLATIN; CURCUMIN; GLUTATHIONE TRANSFERASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LENTIVIRUS VECTOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SULFORAPHANE; THYMIDINE KINASE; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTOME; ANTINEOPLASTIC AGENT; KEAP1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ANTIOXIDANT RESPONSIVE ELEMENT; BINDING AFFINITY; CARCINOGENESIS; CD8+ T LYMPHOCYTE; DNA BINDING; HUMAN; INFLAMMATORY INFILTRATE; LUNG CANCER; LUNG CARCINOGENESIS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SMOKING; SOMATIC MUTATION; SUICIDE GENE THERAPY; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MUTATION; NF-E2-RELATED FACTOR 2;

EID: 84876545580     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2013/746432     Document Type: Review

References (104)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA Cancer Journal for Clinicians 2011 61 2 69 90 2-s2.0-79952232216 10.3322/caac.20107
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M. J., Cancer statistics, 2008. CA Cancer Journal for Clinicians 2008 58 2 71 96 2-s2.0-41349099104 10.3322/CA.2007.0010 (Pubitemid 351521864)
3. Centers for Disease, C and Prevention, Current tobacco use and secondhand smoke exposure among women of reproductive age-14 countries, 2008-2010. MMWR Morbidity and Mortality Weekly Report 2012 61 43 877 882
4. He Y., Jiang B., Li L. S., Secondhand smoke exposure predicted chronic obstructive pulmonary disease and other tobacco related mortality in a 17-years cohort study in China. Chest 2012 142 4 909 918
5. Schottenfeld D., Pass H. I., Etiology and epidemiology of lung cancer. Lung Cancer-Principles and Practice 2005 Philadelphia, Pa, USA Lippincott Williams and Wilkins 3 24
6. Miller Y. E., Pathogenesis of lung cancer: 100 Year report. American Journal of Respiratory Cell and Molecular Biology 2005 33 3 216 223 2-s2.0-24344501624 10.1165/rcmb.2005-0158OE (Pubitemid 41254287)
7. Herbst R. S., Heymach J. V., Lippman S. M., Molecular origins of cancer: lung cancer. The New England Journal of Medicine 2008 359 13 1367 1380 2-s2.0-52649131951 10.1056/NEJMra0802714
8. Taguchi K., Motohashi H., Yamamoto M., Molecular mechanisms of the Keap1- Nrf2 pathway in stress response and cancer evolution. Genes to Cells 2011 16 2 123 140 2-s2.0-78751703950 10.1111/j.1365-2443.2010.01473.x
9. Cho H. Y., Kleeberger S. R., Nrf2 protects against airway disorders. Toxicology and Applied Pharmacology 2010 244 1 43 56
10. Rotblat B., Melino G., Knight R. A., Nrf2 and p53: januses in cancer? Oncotarget 2012 3 11 1272 1283
11. Lee J. H., Khor T. O., Shu L., Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacology and Therapeutics 2013 137 2 153 171
12. Kwak M. K., Kensler T. W., Targeting Nrf2 signaling for cancer chemoprevention. Toxicology and Applied Pharmacology 2010 244 1 66 76 2-s2.0-77649270763 10.1016/j.taap.2009.08.028
13. Sporn M. B., Liby K. T., Nrf2 and cancer: the good, the bad and the importance of context. Nature Reviews Cancer 2012 12 8 564 571
14. Jaiswal A. K., Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radical Biology and Medicine 2004 36 10 1199 1207 2-s2.0-1942520367 10.1016/j.freeradbiomed.2004.02.074 (Pubitemid 38526313)
15. Bobrovnikova-Marjon E., Grigoriadou C., Pytel D., Zhang F., Ye J., Koumenis C., Cavener D., Diehl J. A., PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene 2010 29 27 3881 3895 2-s2.0-77954535031 10.1038/onc.2010.153
16. Cullinan S. B., Zhang D., Hannink M., Arvisais E., Kaufman R. J., Diehl J. A., Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Molecular and Cellular Biology 2003 23 20 7198 7209 2-s2.0-0141752795 10.1128/MCB.23.20.7198-7209.2003 (Pubitemid 37211002)
17. Hayes J. D., McMahon M., Chowdhry S., Dinkova-Kostova A. T., Cancer chemoprevention mechanisms mediated through the keap1- Nrf2 pathway. Antioxidants and Redox Signaling 2010 13 11 1713 1748 2-s2.0-77958130983 10.1089/ars.2010.3221
18. Hu R., Saw C. L. L., Yu R., Kong A. N. T., Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory. Antioxidants and Redox Signaling 2010 13 11 1679 1698 2-s2.0-77958114117 10.1089/ars.2010.3276
19. Perera R. M., Bardeesy N., Cancer: when antioxidants are bad. Nature 2011 475 7354 43 44 2-s2.0-79960034499 10.1038/475043a
20. McCarthy N., Tumorigenesis: oncogene detox programme. Nature Reviews Cancer 2011 11 9 622 623
21. Rangasamy T., Cho C. Y., Thimmulappa R. K., Zhen L., Srisuma S. S., Kensler T. W., Yamamoto M., Petrache I., Tuder R. M., Biswal S., Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. Journal of Clinical Investigation 2004 114 9 1248 1259 2-s2.0-15244356847 10.1172/JCI200421146 (Pubitemid 40385296)
22. Cho H. Y., Reddy S. P., DeBiase A., Yamamoto M., Kleeberger S. R., Gene expression profiling of Nrf2 -mediated protection against oxidative injury. Free Radical Biology and Medicine 2005 38 3 325 343 2-s2.0-11444261268 10.1016/j.freeradbiomed.2004.10.013 (Pubitemid 40081112)
23. Cho H. Y., Imani F., Miller-DeGraff L., Walters D., Melendi G. A., Yamamoto M., Polack F. P., Kleeberger S. R., Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus disease. American Journal of Respiratory and Critical Care Medicine 2009 179 2 138 150 2-s2.0-58449116694 10.1164/rccm.200804-535OC
24. Kim Y. R., Oh J. E., Kim M. S., Kang M. R., Park S. W., Han J. Y., Eom H. S., Yoo N. J., Lee S. H., Oncogenic Nrf2 mutations in squamous cell carcinomas of oesophagus and skin. Journal of Pathology 2010 220 4 446 451 2-s2.0-76749106638 10.1002/path.2653
25. Konstantinopoulos P. A., Spentzos D., Fountzilas E., Francoeur N., Sanisetty S., Grammatikos A. P., Hecht J. L., Cannistra S. A., Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Research 2011 71 15 5081 5089 2-s2.0-79960958309 10.1158/0008-5472.CAN-10-4668
26. Iida K., Itoh K., Kumagai Y., Oyasu R., Hattori K., Kawai K., Shimazui T., Akaza H., Yamamoto M., Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Research 2004 64 18 6424 6431 2-s2.0-4644328941 10.1158/0008-5472.CAN-04-1906 (Pubitemid 39297896)
27. Khor T. O., Huang M. T., Kwon K. H., Chan J. Y., Reddy B. S., Kong A. N., Nrf2 -deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Research 2006 66 24 11580 11584 2-s2.0-33846264538 10.1158/0008-5472.CAN-06-3562 (Pubitemid 46094166)
28. Khor T. O., Huang M. T., Prawan A., Liu Y., Hao X., Yu S., Cheung W. K., Chan J. Y., Reddy B. S., Yang C. S., Kong A. N., Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prevention Research 2008 1 3 187 191 2-s2.0-56249086316 10.1158/1940-6207.CAPR-08-0028
29. Xu C., Huang M. T., Shen G., Yuan X., Lin W., Khor T. O., Conney A. H., Kong A. N. T., Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Research 2006 66 16 8293 8296 2-s2.0-33748089664 10.1158/0008-5472.CAN-06-0300 (Pubitemid 44299200)
30. Klassen C. D., Toxicology: The Basic Science of Poisons 2001 6th McGraw-Hill
31. Witschi H. P., Wallace K. B., Selected examples of free-radical-mediated lung injury. Free Radical Toxicology 1997 New York, NY, USA Taylor and Francis 274 294
32. Hackett N. R., Heguy A., Harvey B. G., O'Connor T. P., Luettich K., Flieder D. B., Kaplan R., Crystal R. G., Variability of antioxidant-related gene expression in the airway epithelium of cigarette smokers. American Journal of Respiratory Cell and Molecular Biology 2003 29 3, part I 331 343 2-s2.0-0042831342 10.1165/rcmb.2002-0321OC (Pubitemid 37093991)
33. Hanahan D., Weinberg R. A., The hallmarks of cancer. Cell 2000 100 1 57 70 2-s2.0-0034614637 (Pubitemid 30046295)
34. Park S.-H., Kim J.-H., Chi G. Y., Kim G.-Y., Chang Y.-C., Moon S.-K., Nam S.-W., Kim W.-J., Yoo Y. H., Choi Y. H., Induction of apoptosis and autophagy by sodium selenite in A549 human lung carcinoma cells through generation of reactive oxygen species. Toxicology Letters 2012 212 3 252 261 10.1016/j.toxlet.2012.06.007
35. Malec V., Gottschald O. R., Li S., Rose F., Seeger W., Hänze J., HIF-1 α signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. Free Radical Biology and Medicine 2010 48 12 1626 1635 2-s2.0-77952671413 10.1016/j.freeradbiomed.2010.03.008
36. Siegel D., Ross D., Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radical Biology and Medicine 2000 29 3-4 246 253 2-s2.0-0033801337 10.1016/S0891-5849(00)00310-5
37. Bauer A. K., Cho H.-Y., Miller-DeGraff L., Targeted deletion of Nrf2 reduces urethane-induced lung tumor development in mice. PLoS One 2011 6 10 e26590
38. Hu Y., Ju Y., Lin D., Mutation of the Nrf2 gene in non-small cell lung cancer. Molecular Biology Reports 2012 39 4 4743 4747 10.1007/s11033-011-1266-4
39. Motohashi H., Yakamoto M., Carcinogenesis and transcriptional regulation through Maf recognition elements. Cancer Science 2007 98 2 135 139 2-s2.0-33845682863 10.1111/j.1349-7006.2006.00358.x (Pubitemid 44941863)
40. Solis L. M., Behrens C., Dong W., Suraokar M., Ozburn N. C., Moran C. A., Corvalan A. H., Biswal S., Swisher S. G., Bekele B. N., Minna J. D., Stewart D. J., Wistuba I. I., Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clinical Cancer Research 2010 16 14 3743 3753 2-s2.0-77954695549 10.1158/1078-0432.CCR-09-3352
41. Hayes J. D., McMahon M., Nrf2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends in Biochemical Sciences 2009 34 4 176 188 2-s2.0-63549121490 10.1016/j.tibs.2008.12.008
42. Muller T., Hengstermann A., Nrf2: friend and foe in preventing cigarette smoking-dependent lung disease. Chemical Research in Toxicology 2012 25 9 1805 1824
43. Shibata T., Ohta T., Tong K. I., Kokubu A., Odogawa R., Tsuta K., Asamura H., Yamamoto M., Hirohashi S., Cancer related mutations in Nrf2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proceedings of the National Academy of Sciences of the United States of America 2008 105 36 13568 13573 2-s2.0-51649130168 10.1073/pnas.0806268105
44. Itoh K., Igarashi K., Hayashi N., Nishizawa M., Yamamoto M., Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Molecular and Cellular Biology 1995 15 8 4184 4193 2-s2.0-0029043995
45. Motohashi H., O'Connor T., Katsuoka F., Engel J. D., Yamamoto M., Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene 2002 294 1-2 1 12 2-s2.0-0037055265 10.1016/S0378-1119(02)00788-6 (Pubitemid 35291008)
46. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J. D., Yamamoto M., Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes and Development 1999 13 1 76 86 2-s2.0-0032953192 (Pubitemid 29045117)
47. Sasaki H., Shitara M., Yokota K., Increased Nrf2 gene (NFE2L2) copy number correlates with mutations in lung squamous cell carcinomas. Molecular Medicine Reports 2012 6 2 391 394
48. Hu L., Miao W., Loignon M., Kandouz M., Batist G., Putative chemopreventive molecules can increase Nrf2 -regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies. Cancer Chemotherapy and Pharmacology 2010 66 3 467 474 2-s2.0-77954664504 10.1007/s00280-009-1182-7
49. Singh A., Boldin-Adamsky S., Thimmulappa R. K., Rath S. K., Ashush H., Coulter J., Blackford A., Goodman S. N., Bunz F., Watson W. H., Gabrielson E., Feinstein E., Biswal S., RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Research 2008 68 19 7975 7984 2-s2.0-54249087596 10.1158/0008-5472.CAN-08-1401
50. Kim H. R., Kim S., Kim E. J., Park J. H., Yang S. H., Jeong E. T., Park C., Youn M. J., So H. S., Park R., Suppression of Nrf2 -driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Lung Cancer 2008 60 1 47 56 2-s2.0-41149177653 10.1016/j.lungcan.2007.09.021 (Pubitemid 351434469)
51. Homma S., Ishii Y., Morishima Y., Yamadori T., Matsuno Y., Haraguchi N., Kikuchi N., Satoh H., Sakamoto T., Hizawa N., Itoh K., Yamamoto M., Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clinical Cancer Research 2009 15 10 3423 3432 2-s2.0-66149168685 10.1158/1078-0432.CCR-08-2822
52. Ebert B., Kisiela M., Malátková P., El-Hawari Y., Maser E., Regulation of human carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer cells. Biochemistry 2010 49 39 8499 8511 2-s2.0-77957288996 10.1021/bi100814d
53. Mahaffey C. M., Mahaffey N. C., Holland W., Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma. Journal of Thoracic Oncology 2012 7 1 34 39 10.1097/JTO.0b013e318233d753
54. Yang H., Wang W., Zhang Y., Zhao J., Lin E., Gao J., He J., The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer. Clinical Lung Cancer 2011 12 3 166 171 2-s2.0-79959614990 10.1016/j.cllc.2011.03.012
55. Inoue D., Suzuki T., Mitsuishi Y., Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Science 2012 103 4 760 766 10.1111/j.1349-7006.2012.02216.x
56. Ohta T., Iijima K., Miyamoto M., Nakahara I., Tanaka H., Ohtsuji M., Suzuki T., Kobayashi A., Yokota J., Sakiyama T., Shibata T., Yamamoto M., Hirohashi S., Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Research 2008 68 5 1303 1309 2-s2.0-40449107193 10.1158/0008-5472.CAN-07-5003 (Pubitemid 351346836)
57. Li Q. K., Singh A., Biswal S., Askin F., Gabrielson E., KEAP1 gene mutations and Nrf2 activation are common in pulmonary papillary adenocarcinoma. Journal of Human Genetics 2011 56 3 230 234 2-s2.0-79953181992 10.1038/jhg.2010.172
58. Singh A., Misra V., Thimmulappa R. K., Lee H., Ames S., Hoque M. O., Herman J. G., Baylin S. B., Sidransky D., Gabrielson E., Brock M. V., Biswal S., Dysfunctional KEAP1- Nrf2 interaction in non-small-cell lung cancer. PLoS Medicine 2006 3 10, article e420 2-s2.0-33750885385 10.1371/journal.pmed.0030420 (Pubitemid 44721825)
59. Mahaffey C. M., Zhang H., Rinna A., Holland W., Mack P. C., Forman H. J., Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma. Free Radical Biology and Medicine 2009 46 12 1650 1657 2-s2.0-67349089075 10.1016/j.freeradbiomed.2009.03.023
60. Gelhaus S. L., Giladb O., Hwang W.-T., Multidrug resistance protein (MRP) 4 attenuates benzo[a]pyrene-mediated DNA-adduct formation in human bronchoalveolar H358 cells. Toxicology Letters 2012 209 1 58 66 10.1016/j.toxlet.2011.11.021
61. Zhang M., Mathur A., Zhang Y., Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells. Cancer Research 2012 72 16 4178 4192
62. Singh A., Wu H., Zhang P., Happel C., Ma J., Biswal S., Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Molecular Cancer Therapeutics 2010 9 8 2365 2376 2-s2.0-77955488723 10.1158/1535-7163.MCT-10-0108
63. Muscarella L. A., Parrella P., D'Alessandro V., la Torre A., Barbano R., Fontana A., Tancredi A., Guarnieri V., Balsamo T., Coco M., Copetti M., Pellegrini F., de Bonis P., Bisceglia M., Scaramuzzi G., Maiello E., Valori V. M., Merla G., Vendemiale G., Fazio V. M., Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics 2011 6 6 710 719 2-s2.0-79958702879 10.4161/epi.6.6.15773
64. Zhang P., Singh A., Yegnasubramanian S., Esopi D., Kombairaju P., Bodas M., Wu H., Bova S. G., Biswal S., Loss of kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Molecular Cancer Therapeutics 2010 9 2 336 346 2-s2.0-76649089973 10.1158/1535-7163.MCT-09-0589
65. Zhan L., Zhangb H., Zhang Q., Regulatory role of KEAP1 and Nrf2 in PPARgamma expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radical Biology and Medicine 2012 53 4 758 768 10.1016/j. freeradbiomed.2012.05.041
66. Niture S. K., Jaiswal A. K., INrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis. Cell Death and Differentiation 2011 18 3 439 451 2-s2.0-79951670106 10.1038/cdd.2010.114
67. Niture S. K., Jaiswal A. K., Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. The Journal of Biological Chemistry 2012 287 13 9873 9886
68. Panani A. D., Roussos C., Cytogenetic and molecular aspects of lung cancer. Cancer Letters 2006 239 1 1 9 2-s2.0-33745650260 10.1016/j.canlet.2005. 06.030 (Pubitemid 43964875)
69. Cancer Genome Atlas Research Network, Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012 489 7417 519 525
70. Shibata T., Saito S., Kokubu A., Suzuki T., Yamamoto M., Hirohashi S., Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway. Cancer Research 2010 70 22 9095 9105 2-s2.0-78549273400 10.1158/0008-5472.CAN-10-0384
71. Suzuki T., Maher J., Yamamoto M., Select heterozygous Keap1 mutations have a dominant-negative effect on wild-type Keap1 in vivo. Cancer Research 2011 71 5 1700 1709 2-s2.0-79952221884 10.1158/0008-5472.CAN-10-2939
72. Malkinson A. M., The genetic basis of susceptibility to lung tumors in mice. Toxicology 1989 54 3 241 271 2-s2.0-0024598143 (Pubitemid 19084024)
73. Malkinson A. M., Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Research 1992 52 supplement 9 2670s 2676s 2-s2.0-0026652576
74. Malkinson A. M., Molecular comparison of human and mouse pulmonary adenocarcinomas. Experimental Lung Research 1998 24 4 541 555 2-s2.0-0031804606 (Pubitemid 28308950)
75. Zimmerli B., Schlatter J., Ethyl carbamate: analytical methodology, occurrence, formation, biological activity and risk assessment. Mutation Research 1991 259 3-4 325 350 2-s2.0-0025863075
76. Shibutani S., Takeshita M., Grollman A. P., Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 1991 349 6308 431 434 2-s2.0-0025981359 10.1038/349431a0 (Pubitemid 21926107)
77. Denicola G. M., Karreth F. A., Humpton T. J., Gopinathan A., Wei C., Frese K., Mangal D., Yu K. H., Yeo C. J., Calhoun E. S., Scrimieri F., Winter J. M., Hruban R. H., Iacobuzio-Donahue C., Kern S. E., Blair I. A., Tuveson D. A., Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011 475 7354 106 110 2-s2.0-79960060305 10.1038/nature10189
78. Satoh H., Moriguchi T., Taguchi K., Takai J., Maher J. M., Suzuki T., Winnard P. T., Raman V., Ebina M., Nukiwa T., Yamamoto M., Nrf2 -deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis 2010 31 10 1833 1843 2-s2.0-77957796093 10.1093/carcin/bgq105
79. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., Herber D. L., Schneck J., Gabrilovich D. I., Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nature Medicine 2007 13 7 828 835 2-s2.0-34447118098 10.1038/nm1609 (Pubitemid 47038194)
80. Mills C. D., Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue. Critical Reviews in Immunology 2001 21 5 399 425 2-s2.0-0035727293 (Pubitemid 34259913)
81. Slocum S. L., Kensler T. W., Nrf2: control of sensitivity to carcinogens. Archives of Toxicology 2011 85 4 273 284
82. Kensler T. W., Wakabayashi N., Nrf2: friend or foe for chemoprevention? Carcinogenesis 2009 31 1 90 99 2-s2.0-74049120454 10.1093/carcin/bgp231 bgp231
83. Shu L., Cheung K. L., Khor T. O., Chen C., Kong A. N., Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis. Cancer and Metastasis Reviews 2010 29 3 483 502 2-s2.0-77957587417 10.1007/s10555-010- 9239-y
84. Patel R., Maru G., Polymeric black tea polyphenols induce phase II enzymes via Nrf2 in mouse liver and lungs. Free Radical Biology and Medicine 2008 44 11 1897 1911 2-s2.0-43249101846 10.1016/j.freeradbiomed.2008.02.006
85. London S. J., Yuan J. M., Chung F. L., Gao Y. T., Coetzee G. A., Ross R. K., Yu M. C., Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China. The Lancet 2000 356 9231 724 729 2-s2.0-0034718294 (Pubitemid 30663242)
86. Talalay P., Fahey J. W., Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. Journal of Nutrition 2001 131 supplement 11 3027S 3033S 2-s2.0-0035170990 (Pubitemid 33070774)
87. Fahey J. W., Talalay P., Antioxidant functions of sulforaphane: a potent inducer of phase II detoxication enzymes. Food and Chemical Toxicology 1999 37 9-10 973 979 2-s2.0-0032841203 10.1016/S0278-6915(99)00082-4 (Pubitemid 29481800)
88. Hayes J. D., Flanagan J. U., Jowsey I. R., Glutathione transferases. Annual Review of Pharmacology and Toxicology 2005 45 51 88 2-s2.0-12844268268 10.1146/annurev.pharmtox.45.120403.095857 (Pubitemid 40261798)
89. Cho H. Y., Reddy S. P., Kleeberger S. R., Nrf2 defends the lung from oxidative stress. Antioxidants and Redox Signaling 2006 8 1-2 76 87 2-s2.0-33644649131 10.1089/ars.2006.8.76 (Pubitemid 43324533)
90. Garg R., Gupta S., Maru G. B., Dietary curcumin modulates transcriptional regulators of phase I and phase II enzymes in benzo[a]pyrene-treated mice: mechanism of its anti-initiating action. Carcinogenesis 2008 29 5 1022 1032 2-s2.0-46949104416 10.1093/carcin/bgn064 (Pubitemid 351982248)
91. Biswas S., Rahman I., Modulation of steroid activity in chronic inflammation: a novel anti-inflammatory role for curcumin. Molecular Nutrition and Food Research 2008 52 9 987 994 2-s2.0-54949154139 10.1002/mnfr.200700259
92. Bauer A. K., Rondini E. A., Review Paper: The role of inflammation in mouse pulmonary neoplasia. Veterinary Pathology 2009 46 3 369 390 2-s2.0-67649961352 10.1354/vp.08-VP-0217-B-REV
93. Malkinson A. M., Role of inflammation in mouse lung tumorigenesis: a review. Experimental Lung Research 2005 31 1 57 82 2-s2.0-11144223531 10.1080/01902140490495020
94. Schottenfeld D., Beebe-Dimmer J., Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer Journal for Clinicians 2006 56 2 69 83 2-s2.0-33645508531 10.3322/canjclin.56.2.69
95. Kerns M., DePianto D., Yamamoto M., Coulombe P. A., Differential modulation of keratin expression by sulforaphane occurs via Nrf2 -dependent and -independent pathways in skin epithelia. Molecular Biology of the Cell 2010 21 23 4068 4075 2-s2.0-78650116927 10.1091/mbc.E10-02-0153
96. Kalpana Deepa Priya D., Gayathri R., Sakthisekaran D., Role of sulforaphane in the anti-initiating mechanism of lung carcinogenesis in vivo by modulating the metabolic activation and detoxification of benzo(a)pyrene. Biomedicine and Pharmacotherapy 2011 65 1 9 16 2-s2.0-79951683540 10.1016/j.biopha.2010.08.009
97. Leinonen H. M., Oxidative stress-regulated lentiviral TK/GCV gene therapy for lung cancer treatment. Cancer Research 2012 72 23 6227 6235
98. Guise C. P., Abbattista M. R., Singleton R. S., Holford S. D., Connolly J., Dachs G. U., Fox S. B., Pollock R., Harvey J., Guilford P., Doñate F., Wilson W. R., Patterson A. V., The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Research 2010 70 4 1573 1584 2-s2.0-76749161362 10.1158/0008-5472.CAN-09-3237
99. Padmanabhan B., Tong K. I., Ohta T., Nakamura Y., Scharlock M., Ohtsuji M., Kang M. I., Kobayashi A., Yokoyama S., Yamamoto M., Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Molecular Cell 2006 21 5 689 700 2-s2.0-33344456501 10.1016/j.molcel.2006.01.013 (Pubitemid 43290735)
100. Singh A., Bodas M., Wakabayashi N., Bunz F., Biswal S., Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxidants and Redox Signaling 2010 13 11 1627 1637 2-s2.0-77958129306 10.1089/ars.2010.3219
101. Travis E. L., Rachakonda G., Zhou X., Nrf2 deficiency reduces life span of mice administered thoracic irradiation. Free Radical Biology and Medicine 2011 51 6 1175 1183 10.1016/j.freeradbiomed.2011.05.038
102. Lee S., Lim M.-J., Kim M.-H., An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2 -dependent antioxidant responses. Free Radical Biology and Medicine 2012 53 4 807 816 10.1016/j.freeradbiomed.2012.05.038
103. Ren D., Villeneuve N. F., Jiang T., Wu T., Lau A., Toppin H. A., Zhang D. D., Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2 -mediated defense mechanism. Proceedings of the National Academy of Sciences of the United States of America 2011 108 4 1433 1438 2-s2.0-79952122321 10.1073/pnas.1014275108
104. Weaver Z., Difilippantonio S., Carretero J., Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. Cancer Research 2012 72 22 5921 5933 10.1158/0008-5472.CAN-12-0736